Rezultati pretraživanja
  1. 25. velj 2019.

    Heart Failure in Women | JACC: Heart Failure : Addressing important issues , stimulating new ideas ⁦⁩ ⁦

  2. Heart Failure and Atrial Fibrillation: 🔸The contribution of inflammation in pathophysiology of and 🔸The emerging role of catheter ablation in management of HFrEF 🔸... and more topics in excellent review 🗞️

  3. 9. lis 2019.

    In , a patient-level comparison of pts in trial vs real-world settings, by race & sex. Compared w/ white pts & men, differences between real-world & trial pts may be exaggerated among black pts & women.

  4. 3. tra 2019.

    Target Dose Versus Maximum Tolerated Dose in : Time to Calibrate and Define Actionable Goals in by ⁦

  5. 9. sij

    Excited to see our paper posted online ! We asked: were there differences in mechanistic biomarkers, cardiac/arterial function, and response to spironolactone among clinical phenogroups of HFpEF in TOPCAT

    Prikaži ovu nit
  6. 20. pro 2019.

    💥💥Excited to Co-Chair + declare reg'n open for 🇨🇦's biggest HF mtg with special guests this yr! + + ! Go to for our jt sessions

    Prikaži ovu nit
  7. 11. tra 2019.

    Just online in our look into the barriers to evidence generation for : research is underpaid, over-complicated, and slow. solution: a new streamlined efficient network.

  8. 30. ruj 2019.
  9. 30. pro 2019.

    How Do Really Work? Clever mediation analyses embedded in EMPAREG OUTCOME & CANVAS offer clues into candidate mechanistic pathways & I discuss caveats to their interpretation in issue

  10. 31. pro 2018.

    Adding a sense of urgency to outpatient medical therapy for w/ reduced EF. Outcomes for chronic HFrEF and many cancers remarkably similar, perception & culture of medical care remarkably different.

  11. 13. stu 2019.

    It's not that causes in and - it's and associated atrial myopathy. Controversial opinion by Milton Packer in must read!

  12. prije 17 sati

    New State-of-the-Art Review: Could this be a game changer in treatment? Check out the methods paper for the trial, which explores the effect of omecamtiv mecarbil, a novel cardiac myosin activator, in chronic .

  13. Highly anticipated HF in Women Special Issue now out for Our latest study embedded within the Do Women & Men Respond Similarly to Therapies in Contemporary HF RCTs?

  14. 11. kol 2019.

    Updated meta-analysis shows effect of based in : -⬇️hospitalizations -⬆️QoL -↔️mortality -Home based rehab equally effective

    Prikaži ovu nit
  15. 23. sij

    State-of-the-Art Review: Both and type 2 can lead to the development and . Are these two consequences of obesity linked to each other? Does HFpEF itself contribute to the risk of systemic thromboembolism?

  16. 4. stu 2019.

    State-of-the-Art Review: Recognize any of these for patients? Drs. , and colleagues discuss the future of wearable technology for HF treatment in this month's issue of .

  17. 29. svi 2019.

    Provocative retrospective study by Braga, et al w editorial by & Narula in -HFrEF pts w cath & non obs CAD Should we define HF-ObCAD v HF-NObCAD? Implications for & cv-PET?

  18. 13. ruj 2019.

    Glad to see our review 'Diagnostic and Therapeutic Gaps in Patients With Co-Occurring Heart Failure and Chronic Obstructive Pulmonary Disease' published online in

  19. 25. stu 2019.

    Our INTERMACS analysis with co-led by and myself now online in special issue of on elderly and HF

    Prikaži ovu nit
  20. 25. sij

    exacerbating medications can potentially contribute to adverse CV outcomes. Are you aware of the pattern of use in older adults following hospitalization? This analysis discusses trends in medicare beneficiaries ≥ 65 years of age.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.